286 related articles for article (PubMed ID: 11379779)
1. Increase in doxorubicin cytotoxicity by inhibition of P-glycoprotein activity with lomerizine.
Shiraki N; Hamada A; Ohmura T; Tokunaga J; Oyama N; Nakano M
Biol Pharm Bull; 2001 May; 24(5):555-7. PubMed ID: 11379779
[TBL] [Abstract][Full Text] [Related]
2. Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activity.
Jonsson O; Behnam-Motlagh P; Persson M; Henriksson R; Grankvist K
Biochem Pharmacol; 1999 Dec; 58(11):1801-6. PubMed ID: 10571255
[TBL] [Abstract][Full Text] [Related]
3. Bromocriptine reverses P-glycoprotein-mediated multidrug resistance in tumor cells.
Shiraki N; Okamura K; Tokunaga J; Ohmura T; Yasuda K; Kawaguchi T; Hamada A; Nakano M
Jpn J Cancer Res; 2002 Feb; 93(2):209-15. PubMed ID: 11856485
[TBL] [Abstract][Full Text] [Related]
4. Reversal of P-glycoprotein mediated multidrug resistance in K562 cell line by a novel synthetic calmodulin inhibitor, E6.
Zhu HJ; Wang JS; Guo QL; Jiang Y; Liu GQ
Biol Pharm Bull; 2005 Oct; 28(10):1974-8. PubMed ID: 16204958
[TBL] [Abstract][Full Text] [Related]
5. Interaction of CJZ3, a lomerizine derivative, with ATPase activity of human P-glycoprotein in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
Ji BS; Li M; He L
Pharmazie; 2010 Jul; 65(7):515-9. PubMed ID: 20662321
[TBL] [Abstract][Full Text] [Related]
6. [Reversal of multidrug resistance by lomerizine in K562/ADM cells].
Zhu HJ; Wu YL; Liu GQ
Yao Xue Xue Bao; 2004 May; 39(5):333-7. PubMed ID: 15338873
[TBL] [Abstract][Full Text] [Related]
7. Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
Xu HB; Li L; Liu GQ
Pharmazie; 2009 Oct; 64(10):660-5. PubMed ID: 19947169
[TBL] [Abstract][Full Text] [Related]
8. Reversal of multidrug resistance in human leukemia K562 by tamolarizine, a novel calcium antagonist.
Miyake N; Fujita R; Ishikawa M; Takayanagi M; Takayanagi Y; Sasaki K
Jpn J Pharmacol; 2000 Mar; 82(3):265-8. PubMed ID: 10887958
[TBL] [Abstract][Full Text] [Related]
9. Reversing Multidrug Resistance in Chemo-resistant Human Lung Adenocarcinoma (A549/DOX) Cells by Algerian Propolis Through Direct Inhibiting the P-gp Efflux-pump, G0/G1 Cell Cycle Arrest and Apoptosis Induction.
Kebsa W; Lahouel M; Rouibah H; Zihlif M; Ahram M; Abu-Irmaileh B; Mustafa E; Al-Ameer HJ; Al Shhab M
Anticancer Agents Med Chem; 2018; 18(9):1330-1337. PubMed ID: 30088453
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Pgp activity and cell cycle-dependent chemosensitivity to doxorubicin in the multidrug-resistant LoVo human colon cancer cell line.
Toffoli G; Corona G; Gigante M; Boiocchi M
Eur J Cancer; 1996 Aug; 32A(9):1591-7. PubMed ID: 8911123
[TBL] [Abstract][Full Text] [Related]
11. Ultrasound-Induced hyperthermia increases cellular uptake and cytotoxicity of P-glycoprotein substrates in multi-drug resistant cells.
Liu Y; Cho CW; Yan X; Henthorn TK; Lillehei KO; Cobb WN; Ng KY
Pharm Res; 2001 Sep; 18(9):1255-61. PubMed ID: 11683237
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin.
Jovelet C; Bénard J; Forestier F; Farinotti R; Bidart JM; Gil S
Eur J Pharm Sci; 2012 Aug; 46(5):484-91. PubMed ID: 22484209
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of doxorubicin activity in multidrug-resistant cells by mefloquine.
Fujita R; Ishikawa M; Takayanagi M; Takayanagi Y; Sasaki K
Methods Find Exp Clin Pharmacol; 2000 Jun; 22(5):281-4. PubMed ID: 11031728
[TBL] [Abstract][Full Text] [Related]
14. The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines.
Consoli U; Priebe W; Ling YH; Mahadevia R; Griffin M; Zhao S; Perez-Soler R; Andreeff M
Blood; 1996 Jul; 88(2):633-44. PubMed ID: 8695811
[TBL] [Abstract][Full Text] [Related]
15. Targeting P-Glycoprotein: Nelfinavir Reverses Adriamycin Resistance in K562/ADR Cells.
Liu W; Meng Q; Sun Y; Wang C; Huo X; Liu Z; Sun P; Sun H; Ma X; Liu K
Cell Physiol Biochem; 2018; 51(4):1616-1631. PubMed ID: 30497065
[TBL] [Abstract][Full Text] [Related]
16. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil.
Wu J; Lu Y; Lee A; Pan X; Yang X; Zhao X; Lee RJ
J Pharm Pharm Sci; 2007; 10(3):350-7. PubMed ID: 17727798
[TBL] [Abstract][Full Text] [Related]
17. Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.
Stein U; Lage H; Jordan A; Walther W; Bates SE; Litman T; Hohenberger P; Dietel M
Int J Cancer; 2002 Feb; 97(6):751-60. PubMed ID: 11857350
[TBL] [Abstract][Full Text] [Related]
18. A novel flavonoid from Fissistigma cupreonitens, 5‑hydroxy‑7,8‑dimethoxyflavanone, competitively inhibited the efflux function of human P-glycoprotein and reversed cancer multi-drug resistance.
Teng YN; Lin KI; Lin YC; Thang TD; Lan YH; Hung CC
Phytomedicine; 2021 May; 85():153528. PubMed ID: 33735724
[TBL] [Abstract][Full Text] [Related]
19. Dual P-Glycoprotein and CA XII Inhibitors: A New Strategy to Reverse the P-gp Mediated Multidrug Resistance (MDR) in Cancer Cells.
Teodori E; Braconi L; Bua S; Lapucci A; Bartolucci G; Manetti D; Romanelli MN; Dei S; Supuran CT; Coronnello M
Molecules; 2020 Apr; 25(7):. PubMed ID: 32290281
[TBL] [Abstract][Full Text] [Related]
20. Design, Synthesis, and Pharmacological Characterization of N-(4-(2 (6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)yl)ethyl)phenyl)quinazolin-4-amine Derivatives: Novel Inhibitors Reversing P-Glycoprotein-Mediated Multidrug Resistance.
Qiu Q; Liu B; Cui J; Li Z; Deng X; Qiang H; Li J; Liao C; Zhang B; Shi W; Pan M; Huang W; Qian H
J Med Chem; 2017 Apr; 60(8):3289-3302. PubMed ID: 28355069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
